Enliven Therapeutics Inc. (ELVN)
Enliven Therapeutics Statistics
Share Statistics
Enliven Therapeutics has 49M shares outstanding. The number of shares has increased by 4.18% in one year.
| Shares Outstanding | 49M |
| Shares Change (YoY) | 4.18% |
| Shares Change (QoQ) | 0.3% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | 31.69M |
| Failed to Deliver (FTD) Shares | 12.84K |
| FTD / Avg. Volume | 5.39% |
Short Selling Information
The latest short interest is 7.1M, so 14.52% of the outstanding shares have been sold short.
| Short Interest | 7.1M |
| Short % of Shares Out | 14.52% |
| Short % of Float | 23.01% |
| Short Ratio (days to cover) | 28.98 |
Valuation Ratios
The PE ratio is -11.9 and the forward PE ratio is -9.83. Enliven Therapeutics's PEG ratio is 1.99.
| PE Ratio | -11.9 |
| Forward PE | -9.83 |
| PS Ratio | 0 |
| Forward PS | 9.1 |
| PB Ratio | 3.42 |
| P/FCF Ratio | -14.46 |
| PEG Ratio | 1.99 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Enliven Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 19.99, with a Debt / Equity ratio of 0.
| Current Ratio | 19.99 |
| Quick Ratio | 19.99 |
| Debt / Equity | 0 |
| Debt / EBITDA | 0 |
| Debt / FCF | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-1.44M |
| Employee Count | 62 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -232K |
| Effective Tax Rate | 0.26% |
Stock Price Statistics
The stock price has increased by 7.21% in the last 52 weeks. The beta is 1.15, so Enliven Therapeutics's price volatility has been higher than the market average.
| Beta | 1.15 |
| 52-Week Price Change | 7.21% |
| 50-Day Moving Average | 21.14 |
| 200-Day Moving Average | 23.44 |
| Relative Strength Index (RSI) | 44.82 |
| Average Volume (20 Days) | 238.24K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -104.55M |
| Net Income | -89.02M |
| EBITDA | -104.55M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -1.89 |
Balance Sheet
The company has 124.12M in cash and 0 in debt, giving a net cash position of 124.12M.
| Cash & Cash Equivalents | 124.12M |
| Total Debt | 0 |
| Net Cash | 124.12M |
| Retained Earnings | -243.47M |
| Total Assets | 325.76M |
| Working Capital | 302.21M |
Cash Flow
In the last 12 months, operating cash flow was -73.19M and capital expenditures -44K, giving a free cash flow of -73.24M.
| Operating Cash Flow | -73.19M |
| Capital Expenditures | -44K |
| Free Cash Flow | -73.24M |
| FCF Per Share | -1.56 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ELVN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for ELVN is $39, which is 95.7% higher than the current price. The consensus rating is "Buy".
| Price Target | $39 |
| Price Target Difference | 95.7% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Stock Splits
The last stock split was on Feb 24, 2023. It was a backward split with a ratio of 1:4.
| Last Split Date | Feb 24, 2023 |
| Split Type | backward |
| Split Ratio | 1:4 |
Scores
| Altman Z-Score | 33.89 |
| Piotroski F-Score | 2 |